All News
Best Rheumatologists (7.19.2024)
This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.
Read Article
JAK Inhibitors Reduce Macular Degeneration
d
Mepage Today
Insurance claims data showed that patients with autoimmune disorders who took Janus kinase (JAK) inhibitors had lower rates of age-related macular degeneration (AMD), hinting that the drugs might treat the common eye disease.
Read Article
3 yr German laboratory study of 71,597 laboratory tests, found 238 positive tests for 13 myositis autoAbs in 209 patients. Pos. results due to Idiopathic inflammatory myopathy in 37(18%), other inflammatory rheum Dz 90 (43%) or NO Rheum Dx 82 (39%) https://t.co/KKg0X1AyU1 https://t.co/FfVfufaUm4
Dr. John Cush RheumNow ( View Tweet)
JAK Inhibitors Reduce Macular Degeneration
Insurance claims data showed that patients with autoimmune disorders who took JAK inhibitors had lower rates of AMD, hinting that the drugs might treat the common eye disease.
https://t.co/bx0UCp0o3r https://t.co/FXSlcFHYXI
Dr. John Cush RheumNow ( View Tweet)
Geography of Arthritis-attributable Pain in the USA
The journal Pain highlights geographic differences in arthritis pain and outcomes, mainly in the Deep South and Appalachia. Severe arthritis pain is more prevalent in the SW, PNW, GA, FL, and ME regions.
https://t.co/e4VuUDWoQt https://t.co/onHbLjAyHx
Dr. John Cush RheumNow ( View Tweet)
JAMA Patient Education Handout on Polymyalgia Rheumatica (PMR)
https://t.co/J1rpcRltM3 https://t.co/gEUcbE1FuP
Dr. John Cush RheumNow ( View Tweet)
Updated EULAR Recommendations on the Treatment of Systemic Sclerosis
Medscape has published an overview to the 2024 updated recommendations for the treatment of SSc presented in Vienna at EULAR 2024.
https://t.co/rmBIfNzJcu https://t.co/uZ2JUdsecZ
Dr. John Cush RheumNow ( View Tweet)
Retrospective study, biopsy-proven Lupus Nephritis pts - 35 of 115 pts (30%) were ANCA positive. ANCA+ LN pts had higher dz activity, predominantly proliferative LN, require more immunosuppressives (CTX, MMF) to achieve remission. https://t.co/jzU8fPYHps https://t.co/E7pMDWJmKt
Dr. John Cush RheumNow ( View Tweet)
Systemic sclerosis sine scleroderma
Systemic sclerosis sine scleroderma (ssSSc), which accounts for nearly 10% of systemic sclerosis (SSc) patients and was first described in 1962, is a subset of SSc.
https://t.co/5NMykTHEtK https://t.co/JNo27zaTrJ
Dr. John Cush RheumNow ( View Tweet)
174 Active RA pts not responding to MTX were started on TCZ. High GM-CSF (> 5 ng/ml and > 10 ng/ml) at baseline were the independent predictors of poor response to TCZ at Wk24. high GM-CSF had signif higher DAS28-ESR & cytokine levels at baseline https://t.co/AreLBseJDq https://t.co/OyIOkiUOT1
Dr. John Cush RheumNow ( View Tweet)
268/279 SLE pts w/ kidney biopsy for proteinuria were Dx w/ lupus nephritis. Proliferative LN (III/IV+V) had higher levels of C1q, chromatin, dsDNA, ribosomal P Abs. C1q & dsDNA independently assoc w/ proliferative LN. AutoAbs decreased in proliferative LN https://t.co/oq3JhrFlz8 https://t.co/nxQBZvoOzP
Dr. John Cush RheumNow ( View Tweet)
Full read overview of myositis associated - ILD (and treatments), including:
- Case examples
- Antisynthetase Syndrome
- Anti-MDA5 Amyopathic DM
- Interstitial Lung Disease in Myositis https://t.co/PhfuuBHOYf https://t.co/OC1GmWkYyO
Dr. John Cush RheumNow ( View Tweet)
Problems With Laboratory Tests in the Management of RA
https://t.co/kUYivP7SHW https://t.co/nFtB75N0jQ
Dr. John Cush RheumNow ( View Tweet)
Enhance your clinical practice with insights from the EULAR 2024 Poster Hall Presentations, now on https://t.co/V10S4oVFsv. This year's conference showcases pivotal research in rheumatology. Visit https://t.co/gL38TVZRkM to stay at the forefront of medical innovation. https://t.co/cZontmAPTq
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Metrics Used by Rheumatologists in RA
https://t.co/7Qr4cYvqp1 https://t.co/1FnyNpfhqi
Dr. John Cush RheumNow ( View Tweet)
Pain in RA: Different Drugs for Different Mechanisms
https://t.co/pOETFkTIkS https://t.co/Vn5zgrYsKR
Dr. John Cush RheumNow ( View Tweet)
Top 20 Best Rheumatology Hospitals - 2024
Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 7th year in a row they have held this spot.
https://t.co/ZHogsqVR5H https://t.co/45qm4Li4ii
Dr. John Cush RheumNow ( View Tweet)
Study of 478 CA pts Rx w. anti-PD-(L)1 Ab or anti-CTLA4 Ab - 28 (6%) had pre-existing Autoimmune Dz (AI). irAE (w/ checkpoint inhib) were higher w/ preexisting AI (57% vs 35%), but activity of AI was not related to irAEs occurrence.
https://t.co/CHIdaH91qR https://t.co/XuaLk4D205
Dr. John Cush RheumNow ( View Tweet)
Prospective cohort study from 474 055 participants in UK Biobank, finds long-term exposure to air pollutants, NO2 etc, assoc w/ a 19% to 47% increased risk incident psoriasis. Air pollution and genetic predisposition also significantly incr incident PsO https://t.co/ogX81ybU3l https://t.co/Mvd6tAj2j6
Dr. John Cush RheumNow ( View Tweet)
IL-17 inhibitor Brodalumab is not often talked about, but its approved for PsO & PsA. German study of 227 PsO w/ 37 PsA pts Rx w/ BRO - good, rapid response by 3 mos. 1 year drug survival rate was 76.2%, (mean discontinuation=8.3 mos. https://t.co/4byFoc96Zs https://t.co/sPomX0s8aa
Dr. John Cush RheumNow ( View Tweet)
